文献速递乳腺癌

OlympiA研究患者报告结局:gBRCA1/2突变高危HER2阴性早期乳腺癌辅助奥拉帕利 vs 安慰剂的III期随机对照试验

Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
PubMed 文献 · J Clin Oncol · 2024-02-01

OlympiA是一项III期随机安慰剂对照试验,评估gBRCA1/2突变高危HER2阴性早期乳腺癌完成(新)辅助化疗、手术和放疗后,1年辅助奥拉帕利对比安慰剂的患者报告结局。主要终点为疲乏,奥拉帕利组疲乏严重度在6和12个月时统计学显著高于安慰剂组,但未达预设的临床有意义标准(≥3分),18和24个月时两组无显著差异。恶心呕吐严重度在6和12个月时奥拉帕利组更差。奥拉帕利组治疗相关症状有限,治疗结束后一般缓解。

要点

  • 奥拉帕利组疲乏严重度在6和12个月时统计学显著高于安慰剂组,但未达预设临床有意义标准(≥3分)。
  • 18和24个月时两组疲乏严重度无显著差异。
  • 奥拉帕利组恶心呕吐严重度在6和12个月时更差。

核心结论

  • 奥拉帕利治疗相关症状有限,一般在治疗结束后缓解;奥拉帕利组和安慰剂组功能评分相似,在(新)辅助化疗后24个月内缓慢改善;奥拉帕利组疲乏严重度无临床有意义的持续。

研究设计与样本

  • OlympiA是一项III期随机安慰剂对照试验,比较1年辅助奥拉帕利 vs 安慰剂,入组gBRCA1/2突变高危HER2阴性早期乳腺癌患者,完成(新)辅助化疗、手术和放疗后。
  • 数据收集时间点为随机分组前及6、12、18和24个月。
  • 主要终点为疲乏,采用慢性病治疗功能评估-疲乏量表(FACIT-F)测量;次要终点采用欧洲癌症研究与治疗组织生活质量核心30项问卷(EORTC QLQ-C30)评估,包括恶心呕吐、腹泻和多个功能领域。
  • 采用重复测量混合模型比较治疗组间评分;主要终点双侧P值<.05为统计学显著;所有次要终点均为描述性。

主要发现

  • 6个月时疲乏严重度奥拉帕利组 vs 安慰剂组:新辅助化疗组差异-1.3(95%CI -2.4至-0.2;P=.022);辅助化疗组差异-1.3(95%CI -2.3至-0.2;P=.017);统计学显著但未达预设临床有意义标准(≥3分)。
  • 12个月时疲乏严重度奥拉帕利组 vs 安慰剂组:新辅助化疗组差异-1.6(95%CI -2.8至-0.3;P=.017);辅助化疗组差异-1.3(95%CI -2.4至-0.2;P=.025);统计学显著但未达预设临床有意义标准(≥3分)。
  • 18和24个月时两组疲乏严重度无显著差异。
  • 6个月时恶心呕吐严重度奥拉帕利组 vs 安慰剂组:新辅助化疗组6.0(95%CI 4.1至8.0);辅助化疗组5.3(95%CI 3.4至7.2);12个月时:新辅助化疗组6.4(95%CI 4.4至8.3);辅助化疗组4.5(95%CI 2.8至6.1)。
  • 治疗期间其他一些症状组间有一些临床有意义差异,但功能子量表或总体健康状况无临床有意义差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The OlympiA randomized phase III trial compared 1 year of olaparib (OL) or placebo (PL) as adjuvant therapy in patients with germline BRCA1/2, high-risk human epidermal growth factor receptor 2-negative early breast cancer after completing (neo)adjuvant chemotherapy ([N]ACT), surgery, and radiotherapy. The patient-reported outcome primary hypothesis was that OL-treated patients may experience greater fatigue during treatment. METHODS: Data were collected before random assignment, and at 6, 12, 18, and 24 months. The primary end point was fatigue, measured with the Functional Assessment of Chronic Illness Therapy-Fatigue scale. Secondary end points, assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30 item, included nausea and vomiting (NV), diarrhea, and multiple functional domains. Scores were compared between treatment groups using mixed model for repeated measures. Two-sided P values <.05 were statistically significant for the primary end point. All secondary end points were descriptive. RESULTS: One thousand five hundred and thirty-eight patients (NACT: 746, ACT: 792) contributed to the analysis. Fatigue severity was statistically significantly greater for OL versus PL, but not clinically meaningfully different by prespecified criteria (≥3 points) at 6 months (diff OL v PL: NACT: -1.3 [95% CI, -2.4 to -0.2]; P = .022; ACT: -1.3 [95% CI, -2.3 to -0.2]; P = .017) and 12 months (NACT: -1.6 [95% CI, -2.8 to -0.3]; P = .017; ACT: -1.3 [95% CI, -2.4 to -0.2]; P = .025). There were no significant differences in fatigue severity between treatment groups at 18 and 24 months. NV severity was worse in patients treated with OL compared with PL at 6 months (NACT: 6.0 [95% CI, 4.1 to 8.0]; ACT: 5.3 [95% CI, 3.4 to 7.2]) and 12 months (NACT: 6.4 [95% CI, 4.4 to 8.3]; ACT: 4.5 [95% CI, 2.8 to 6.1]). During treatment, there were some clinically meaningful differences between groups for other symptoms but not for function subscales or global health status. CONCLUSION: Treatment-emergent symptoms from OL were limited, generally resolving after treatment ended. OL- and PL-treated patients had similar functional scores, slowly improving during the 24 months after (N)ACT and there was no clinically meaningful persistence of fatigue severity in OL-treated patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ganz PA, Bandos H, Španić T, et al. Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer. J Clin Oncol. 2024. PMID: 38301187. doi:10.1200/JCO.23.01214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。